Clay Siegall is a respected science professional who is recognized for the tremendous contributions that he has made towards the development of cancer treatments. He is highly skilled in biotechnology and genetics. Seigall was once hired by the various government and private research institutions to help in the development of gene-based cures. He has had a positive impact for the past three decades of his career. In 1998, Clay worked with different biotechnology professionals to start Seattle Genetics. The company’s primary focus is to deal with the development of cancer therapies that are safer for human treatment. Chemotherapies that are used by medical professional in curing the deadly disease are less efficient and have adverse side effects.
Over the years, Seattle Genetics has developed into a research hub that is served by several biotechnology experts. Some of the therapies that it has created have been licensed by the FDA. The firm was a pioneer in the formation of the antibody drug conjugates technology that is used in manufacturing cancer drugs. Seattle Genetics has generated millions of dollars from selling internally manufactured ADC drugs, offering licenses to pharmaceutical firms to use the technology, and joining effort with various multinational corporations to produce drugs externally. It has worked with companies such as Genentech, Bayer, and Takeda Pharmaceuticals. Seatle Genetics currently has more than 900 employees, and it is considered as the leading biotech firm in Washington. It enjoys a market that is worth about $10 billion.
Siegall has displayed excellent management skills for the past two decades that he has been the chairman of Seattle Genetics. He has led the researchers at the firm in establishing cancer cures that have saved the lives of many patients. Seattle Genetics is still focused on improving its cancer therapies by customizing them. Clay believes in the staff members of the company since they have assisted it in impacting the pharmaceuticals industry. The company’s shares rose from $20 to $66 in mid-May.
The biotechnology professional has acquired a lot of experience during his career life. This has enabled him to be appointed as a board member of leading companies such as Ultragenyx, BioPharmaceuticals, and Mirna Therapeutics. Clay has accomplished a lot during his research career at Seattle Genetics. He has discovered several new cures and holds 15 biotechnology patents. He has also published over 70 research-based articles. Siegall has a Ph.D. in genetics and a biotechnology degree.